# Metastatic Castration-Resistant Prostate Cancer (mCRPC) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc

> 1 upcoming FDA catalyst in metastatic Castration-Resistant Prostate Cancer (mCRPC): AAA617 (NVS) on November 2026 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2026 to Feb 2027 | [Pluvicto topline data readout](https://sec-api.dev/pdufa/pluvicto) | NVS | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06004661 (Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06004661)) |
| Nov 2026 to Feb 2027 | [AAA617 topline data readout](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |
| November 2026 | [Pluvicto primary completion](https://sec-api.dev/pdufa/pluvicto) | NVS | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06004661 (Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06004661)) |
| November 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |

## Drugs

- [Pluvicto](https://sec-api.dev/pdufa/pluvicto) (NVS)
- [AAA617](https://sec-api.dev/pdufa/aaa617) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Castration-Resistant Prostate Cancer (mCRPC) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc

```bibtex
@misc{secapidev_indications_metastatic_castration_resistant_prostate_cancer_mcrpc_20261116,
  title        = {Metastatic Castration-Resistant Prostate Cancer (mCRPC) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_castration_resistant_prostate_cancer_mcrpc_20261116","title":"Metastatic Castration-Resistant Prostate Cancer (mCRPC) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
